JonesTrading analyst Soumit Roy has reiterated their neutral stance on CLLS stock, giving a Hold rating on May 13.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Soumit Roy’s rating is based on the anticipation of upcoming data updates and strategic developments for Cellectis SA. The company is expected to release significant data from its Phase 1 trials for BALLI-01 and NATHALI-01 in the second half of 2025. These updates are crucial for assessing the durability and potential of their assets, which are necessary for moving towards registration-enabling trials.
Additionally, Cellectis is advancing its research and development programs in collaboration with AstraZeneca, focusing on innovative therapies for hematological malignancies and solid tumors. Despite having a substantial cash reserve, the company’s future progress hinges on the outcomes of these trials and strategic developments. Therefore, the Hold rating reflects a cautious stance while awaiting further clarity on these key catalysts.
According to TipRanks, Roy is an analyst with an average return of -28.5% and a 16.97% success rate. Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Elicio Therapeutics, and Chimerix.
In another report released on May 13, Wells Fargo also maintained a Hold rating on the stock with a $3.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue